Novel Therapies for Hidradenitis Suppurativa Produce Rapid, Deepening Responses
https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — DENVER — Two therapeutic candidates for severe hidradenitis suppurativa (HS) achieved major responses that proved durable in randomized trials reported here. Sonelokimab, an IL-17A/F inhibitor, achieved skin clearance of at least 75%…
